These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. Roux C; Reginster JY; Fechtenbaum J; Kolta S; Sawicki A; Tulassay Z; Luisetto G; Padrino JM; Doyle D; Prince R; Fardellone P; Sorensen OH; Meunier PJ J Bone Miner Res; 2006 Apr; 21(4):536-42. PubMed ID: 16598373 [TBL] [Abstract][Full Text] [Related]
5. Addressing and meeting the needs of osteoporotic patients with strontium ranelate: a review. Boonen S Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S21-7. PubMed ID: 16735842 [TBL] [Abstract][Full Text] [Related]
6. Osteoporosis: from early fracture prevention to better bone health with strontium ranelate. Cortet B Rheumatology (Oxford); 2009 Oct; 48 Suppl 4():iv14-9. PubMed ID: 19783589 [TBL] [Abstract][Full Text] [Related]
7. Protelos: nonvertebral and hip antifracture efficacy in postmenopausal osteoporosis. Adami S Bone; 2006 Feb; 38(2 Suppl 1):23-7. PubMed ID: 16434247 [TBL] [Abstract][Full Text] [Related]
8. Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age. Seeman E; Boonen S; Borgström F; Vellas B; Aquino JP; Semler J; Benhamou CL; Kaufman JM; Reginster JY Bone; 2010 Apr; 46(4):1038-42. PubMed ID: 20026265 [TBL] [Abstract][Full Text] [Related]
9. Continuous broad protection against osteoporotic fractures with strontium ranelate. Ferrari S Rheumatology (Oxford); 2009 Oct; 48 Suppl 4():iv20-4. PubMed ID: 19783590 [TBL] [Abstract][Full Text] [Related]
10. Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia. Seeman E; Devogelaer JP; Lorenc R; Spector T; Brixen K; Balogh A; Stucki G; Reginster JY J Bone Miner Res; 2008 Mar; 23(3):433-8. PubMed ID: 17997711 [TBL] [Abstract][Full Text] [Related]
11. Strontium ranelate: an increased bone quality leading to vertebral antifracture efficacy at all stages. Ortolani S; Vai S Bone; 2006 Feb; 38(2 Suppl 1):19-22. PubMed ID: 16455319 [TBL] [Abstract][Full Text] [Related]
12. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years. Reginster JY; Bruyère O; Sawicki A; Roces-Varela A; Fardellone P; Roberts A; Devogelaer JP Bone; 2009 Dec; 45(6):1059-64. PubMed ID: 19679207 [TBL] [Abstract][Full Text] [Related]
13. Strontium ranelate in the prevention of osteoporotic fractures. Reginster JY; Malaise O; Neuprez A; Bruyere O Int J Clin Pract; 2007 Feb; 61(2):324-8. PubMed ID: 17263720 [TBL] [Abstract][Full Text] [Related]
14. A new treatment for post-menopausal osteoporosis: strontium ranelate. Rizzoli R J Endocrinol Invest; 2005; 28(8 Suppl):50-7. PubMed ID: 16323829 [TBL] [Abstract][Full Text] [Related]
15. Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. Seeman E; Vellas B; Benhamou C; Aquino JP; Semler J; Kaufman JM; Hoszowski K; Varela AR; Fiore C; Brixen K; Reginster JY; Boonen S J Bone Miner Res; 2006 Jul; 21(7):1113-20. PubMed ID: 16813532 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years. Hiligsmann M; Bruyère O; Reginster JY Bone; 2010 Feb; 46(2):440-6. PubMed ID: 19716940 [TBL] [Abstract][Full Text] [Related]
17. Strontium ranelate: the first agent of a new therapeutic class in osteoporosis. Neuprez A; Hiligsmann M; Scholtissen S; Bruyere O; Reginster JY Adv Ther; 2008 Dec; 25(12):1235-56. PubMed ID: 19066755 [TBL] [Abstract][Full Text] [Related]
18. Prospective assessment of thoracic kyphosis in postmenopausal women with osteoporosis. Roux C; Fechtenbaum J; Kolta S; Said-Nahal R; Briot K; Benhamou CL J Bone Miner Res; 2010 Feb; 25(2):362-8. PubMed ID: 19594302 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence. Inderjeeth CA; Foo AC; Lai MM; Glendenning P Bone; 2009 May; 44(5):744-51. PubMed ID: 19130909 [TBL] [Abstract][Full Text] [Related]
20. The effects of strontium ranelate in Asian women with postmenopausal osteoporosis. Hwang JS; Chen JF; Yang TS; Wu DJ; Tsai KS; Ho C; Wu CH; Su SL; Wang CJ; Tu ST Calcif Tissue Int; 2008 Nov; 83(5):308-14. PubMed ID: 18843436 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]